Bladder Cancer Coverage from Every Angle
Advertisement
Advertisement

AACR 2021: Survival Outcomes by Treatment Response From IMvigor130 in Urothelial Cancer

By: Vanessa A. Carter, BS
Posted: Friday, April 16, 2021

At the American Association for Cancer Research (AACR) Annual Meeting 2021, Enrique Grande, MD, PhD, of the MD Anderson Cancer Center Madrid, Spain, and colleagues presented the findings of their exploratory analysis of second interim overall survival data by the response to treatment from the phase III IMvigor130 trial in urothelial carcinoma (Abstract CT187). The researchers discovered that although the overall survival benefit of both groups was consistent with the intent-to-treat population results from the first interim analysis, patients treated with cisplatin (along with gemcitabine) may derive a more significant survival benefit from the addition of atezolizumab to their regimen than did those patients treated with carboplatin (along with gemcitabine).

The IMvigor130 study focused on 502 patients with previously untreated metastatic urothelial carcinoma. Patients were randomly assigned 1:1:1 to one of three arms: arm A: atezolizumab plus platinum/gemcitabine; arm B: atezolizumab monotherapy; arm C: placebo plus platinum/gemcitabine; then they were further divided into two groups based on progressive disease status. Individuals were also randomly assigned to receive either cisplatin or carboplatin chemotherapy based on investigator preference. Arms A and C were used in this second interim survival analysis.

Patients from arm A with no progressive disease during induction who were in the intent-to-treat, cisplatin-treated, and carboplatin-treated groups had a median overall survival of 20.5, 28.2, and 18.5 months, respectively; patients in arm C had a median overall survival of 18.8, 19.9, and 18.8 months, respectively. Participants who had no progressive disease in the intent-to-treat group had a hazard ratio of 0.86. Those treated with cisplatin had a lower hazard ratio (0.60) than individuals on carboplatin (0.97).

Participants from arm A with progressive disease during induction had lower median overall survival in the intent-to-treat (4.3 months), cisplatin-treated (6.6 months), and carboplatin-treated groups (3.8 months); patients in Arm C had even a lower median overall survival of 3.3, 2.5, and 3.4 months, respectively.

Disclosure: For full disclosures of the study authors, visit abstractsonline.com.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.